Antigenics withdraws Oncophage MAA

Antigenics Inc. (NASDAQ:AGEN) withdrew an MAA for Oncophage vitespen after EMEA's CHMP formally adopted a negative opinion on the compound for the adjuvant treatment of renal cell carcinoma (RCC). CHMP told the company last month to expect a negative opinion. Antigenics will evaluate its options, including a potential resubmission. Antigenics was off $0.06 to $0.90 on Friday.

The committee also issued negative opinions for Nenad lisuride transdermal patch from Axxonis Pharma AG (Berlin, Germany) to treat restless legs syndrome (RLS); and Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) to expand the label to include glioblastoma after relapse. ...